AEterna Zentaris

About:

AEterna Zentaris is a drug development company that specializes in oncology and endocrine therapy.

Website: https://www.zentaris.com

Description:

AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and its Phase II program in multiple cancers, including metastatic colon cancer, as well as Phase II program with AEZS-108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, the Company's program is the reactivation of a Phase III trial with AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for the diagnosis of GH deficiency in adults (AGHD).

Total Funding Amount:

$82.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Quebec, Quebec, Canada

Founded Date:

1991-01-01

Contact Email:

bgoett(AT)aezsinc.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2021-02-16

IPO Status:

Public

Industries:

© 2025 bioDAO.ai